Gawande looks to remove waste as he gears up to head healthcare initiative

After his  appointment as CEO of the new Amazon-Berkshire Hathaway-JPMorgan Chase healthcare venture, Atul Gawande, MD, stated the undertaking will look to target wasteful spending, while providing better outcomes and satisfaction and removing “some of the middlemen" from the system.

“My job for them is to figure out ways that we’re going to drive better outcomes, better satisfaction with care and better cost efficiency with new models that can be incubated for all,” Gawande said.

The venture is slated to target three types of waste in the healthcare system including administrative costs, high prices and “improper” healthcare usage, according to reporting from Bloomberg.com.

To read more, click the link below:

""

As a senior news writer for TriMed, Subrata covers cardiology, clinical innovation and healthcare business. She has a master’s degree in communication management and 12 years of experience in journalism and public relations.

Around the web

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.